<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483688</url>
  </required_header>
  <id_info>
    <org_study_id>CBMG-C2017007</org_study_id>
    <nct_id>NCT03483688</nct_id>
  </id_info>
  <brief_title>A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects</brief_title>
  <official_title>A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellular Biomedicine Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy
      of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include the following sequential phases: Screening, Pre- Treatment (Cell
      Product Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>incidence of adverse events (AEs) and serious adverse events (SAEs)
events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>The ORR will be assessed at weeks 4 ，weeks 12 ，months 6 and months 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission (DOR)</measure>
    <time_frame>12 months</time_frame>
    <description>The DOR will be assessed at months 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>12 months</time_frame>
    <description>The PFS will be assessed at months 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate（OSR）</measure>
    <time_frame>12 months</time_frame>
    <description>The OSR will be assessed at weeks 12 ，months 6 and months 12</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>B-cell Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>CD19-directed CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19-directed CAR-T cells</intervention_name>
    <description>CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg</description>
    <arm_group_label>CD19-directed CAR-T cells</arm_group_label>
    <other_name>Anti-CD19 chimeric antigen receptor T cells (C- CAR011)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteered to participate in this study and signed informed consent.

          -  Age 18-70 years old, male or female.

          -  Relapse or refractory B cell non-Hodgkin's lymphoma ,Histologically diagnosed as
             DLBCL,follicular lymphoma and Mantle cell lymphoma according to the NCCN. nonHodgkin's
             lymphoma Clinical Practice Guidelines (2017 Version 1)

               1. DLBCL and Follicular Lymphoma (stage Ⅲ-Ⅳ, grade Ⅲb).

                    1. Progressive disease after the last standard chemotherapy regimens.

                    2. Stable disease after the last standard chemotherapy regimens(at least 4
                       cycles of first-line therapy or 2 cycles of later-line therapy).

                    3. Relapse or progressive disease within 12 months after autologous stem cell
                       transplantation (SCT).

               2. Follicular lymphoma (stage Ⅲ-Ⅳ) (gradeⅠ-Ⅲa)

                    1. Relapse or progressive disease within 1 year after the last standard
                       chemotherapy regimens(At least 2 combination chemotherapy regimens).

                    2. Stable disease after the last standard chemotherapy regimens(at least 2
                       cycles of combination chemotherapy regimens).

               3. Mantle cell lymphoma

                    1. Relapse after 1st CR or persistent disease, and not eligible or appropriate
                       for SCT.

                    2. Relapse or progressive disease within 1 year after the last chemotherapy
                       regimens(at least 4 cycles of first-line therapy or 2 cycles of later- line
                       therapy).

                    3. Relapse or progressive disease within 12 months after autologous SCT.

          -  All subjects must have received anti-CD20 monoclonal antibody (unless tumor is
             CD20-negative) and anthracycline-containing chemotherapy regimens according to NCCN
             non-Hodgkin lymphoma Clinical Practice Guidelines (2017 Version 1).

          -  At least one measurable lesion per revised IWG Response Criteria (the longest diameter
             of the tumor ≥ 1.5cm).

          -  Expected survival ≥ 12 weeks.

          -  ECOG score 0-1.

          -  Left ventricular ejection fraction (LVEF) ≥ 50% (detected by echocardiography).

          -  No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92%
             on room air.

          -  At least 2 weeks from receiving previous treatment (radiotherapy or chemotherapy)
             prior to leukapheresis.

          -  No contraindications of leukapheresis.

          -  Female subjects in childbearing age, their serum or urine pregnancy test must be
             negative, and must agree to take effective contraceptive measures during the trial.

        Exclusion Criteria:

          -  History of allergy to cellular products.

          -  Laboratory tests: absolute neutrophil count &lt; 1.0 × 10^9 /L, platelet count &lt; 50×10^9
             /L, serum albumin &lt; 30 g/L,serum bilirubin &gt; 1.5 ULN, serum creatinine &gt; ULN, ALT/AST
             &gt; 3 ULN.

          -  History of CAR T cell therapy or any other genetically modified T cell therapy.

          -  Relapse after allogeneic hematopoietic stem cell transplantation.

          -  Active infections that require treatment (uncomplicated urinary tract infections and
             bacterial pharyngitis are allowed), prophylactic antibiotic, antiviral and antifungal
             treatment are permitted.

          -  Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as
             acquired or congenital immune deficiency diseases, including but not limited to HIV
             infection.

          -  Class III or IV heart failure according to the NYHA Heart Failure Classifications.

          -  QT interval prolongation ≥ 450 ms.

          -  History of epilepsy or other central nervous system disorders.

          -  Evidence of CNS lymphoma by head enhancement scan or magnetic resonance imaging.

          -  History of other primary cancers, with the following exceptions.

               1. Excisional non-melanoma (e.g. cutaneous basal cell carcinoma).

               2. Cured in situ carcinoma (e.g. cervical cancer, bladder cancer, breast cancer).

          -  Autoimmune diseases that require treatment, immune deficiency diseases or other
             diseases that require immunosuppressive therapy.

          -  Used of systemic steroids within two weeks (using inhaled steroids is an exception).

          -  Women who are pregnant or lactating, or who have breeding intent in 6 months.

          -  Participated in any other clinical trial within three months.

          -  Any situation that investigators believe the risk of the subjects is increased or
             results of the trial are disturbed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daobin Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daobin Zhou</last_name>
    <phone>010-69155020</phone>
    <email>zhoudb@pumch.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lu Zhang</last_name>
    <phone>010-69155660</phone>
    <email>pumczhanglu@163.com</email>
  </overall_contact_backup>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell Non-Hodgkin Lymphoma</keyword>
  <keyword>Refractory</keyword>
  <keyword>Relapsed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

